泰德·迈尔斯加入Cellarity担任首席执行官-动脉网

Ted Myles Joins Cellarity as Chief Executive Officer

CISION 等信源发布 2025-05-12 20:00



可切换为仅中文







Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner

迈尔斯（Myles），一位生物制药行业的资深人士，还将作为首席执行官合伙人加入旗舰先锋公司（Flagship Pioneering）。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

May 12, 2025

2025年5月12日

/PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of

/PRNewswire/ -- Cellarity，一家改变药物创造方式的生命科学公司，以及Flagship Pioneering，生物平台创新公司，今天宣布任命

Ted Myles

泰德·迈尔斯

as Chief Executive Officer of Cellarity and CEO-Partner at Flagship.

作为 Cellarity 的首席执行官和 Flagship 的首席执行官合伙人。

继续阅读

Ted Myles

泰德·迈尔斯

(PRNewsfoto/Flagship Pioneering)

（PRNewsfoto/旗舰先锋）

Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating Officer of Scholar Rock where he led the company through its evolution from early development-stage through a successful Phase 3 registrational study and raised more than .

迈尔斯是一位资深的生物医药行业领导者，拥有深厚的经验和建立临床及商业化阶段公司的成功记录。此前，他曾担任 Scholar Rock 的首席财务官和首席运营官，在任期间带领公司从早期开发阶段发展到成功完成三期注册研究，并筹集了超过数亿美元的资金。

$1 billion

10亿美元

in capital to advance the company's product and pipeline strategy. Prior to that, Myles served as CFO and COO of AMAG Pharmaceuticals, Inc. (acquired by Covis Pharmaceuticals), CFO and COO of Ocata Therapeutics, Inc. (acquired by Astellas), and CFO and Vice President of Operations at PrimeraDx, Inc.

总部设在首都，以推动公司的产品和渠道战略。在此之前，Myles曾担任AMAG制药公司（被Covis制药收购）的首席财务官和首席运营官，Ocata Therapeutics公司（被Astellas收购）的首席财务官和首席运营官，以及PrimeraDx公司的首席财务官和运营副总裁。

(acquired by Qiagen). He holds an MBA from .

（已被Qiagen收购）。他持有MBA学位。

John M. Olin School

约翰·M·奥林商学院

of Business at

商学院于

Washington University

华盛顿大学

在

St. Louis

圣路易斯

and a B.S. in Business Administration from the

工商管理学士学位

University of Hartford

哈特福德大学

。

'As Cellarity approaches a significant inflection point with its first anticipated clinical study this year, Ted's executive leadership experience across the development spectrum will be essential to delivering on and expanding the value of Cellarity's scientific platform and product development strategy,' said Stephen Berenson, Chairman of the Cellarity Board and Managing Partner Emeritus of Flagship Pioneering.

“随着 Cellarity 即将迎来今年首个预期的临床研究这一重要转折点，Ted 在开发领域的执行领导经验将对实现并拓展 Cellarity 科学平台和产品开发战略的价值至关重要，”Cellarity 董事会主席兼 Flagship Pioneering 荣誉管理合伙人 Stephen Berenson 表示。

'On behalf of the entire Board, we welcome Ted and look forward to a fruitful partnership.'.

“代表全体董事会，我们欢迎泰德，并期待富有成效的合作。”

'Cellarity is a powerhouse of AI-powered biotechnology as it brings data, biology, and chemistry together in truly distinctive ways. I am impressed by the strength of its end-to-end platform and the novelty of the programs it is producing for important indications, and I'm excited to lead such a strong team as we move into the clinical stage of program development and extend the platform into new disease areas,' said Myles.

“Cellarity 是一家强大的人工智能生物技术公司，因为它以真正独特的方式将数据、生物学和化学结合在一起。其端到端平台的实力以及它为重要适应症开发的项目的新颖性给我留下了深刻印象。当我们进入项目开发的临床阶段并将平台扩展到新的疾病领域时，我为能领导这样一支强大的团队感到兴奋。”Myles 说道。

'I look forward to partnering with leaders across Cellarity as we work to bring novel, world class medicines to patients.'.

“我期待与Cellarity的各位领导者合作，为患者带来新颖且世界级的药物。”

'At Flagship, we are enthusiastic about Cellarity's accelerated trajectory fueled by an increasingly mature platform capable of producing completely novel medicines that target complex disease biology in an entirely unique way,' said

‘在旗舰公司，我们对Cellarity由日益成熟的平台推动的加速发展轨迹充满热情，该平台能够以完全独特的方式生产针对复杂疾病生物学的全新药物，’

Noubar Afeyan

努巴尔·阿费扬

, Ph.D., Co-founder of Cellarity and Founder and CEO of Flagship Pioneering. 'We congratulate the company on Ted's appointment – he is the right leader to take the helm given his executive acumen and inspired leadership, and we know that he will be a valued voice across the Flagship ecosystem.'

博士，Cellarity联合创始人，Flagship Pioneering创始人兼首席执行官。“我们祝贺公司任命Ted，他是掌舵的理想领袖，凭借其出色的管理才能和鼓舞人心的领导力，我们知道他将在Flagship生态系统中成为重要的声音。”

Cellarity's drug discovery approach starts with the understanding of dysregulated pathways in diseased human cells and reveals novel targets and medicines to generate first-in-class approaches with higher likelihood of success in the clinic. Through its industry-leading AI/ML-enabled platform and using single-cell transcriptomics, the company is uncovering novel druggable biology for complex diseases and advancing a rich and highly differentiated pipeline of small molecule programs.

Cellarity的药物发现方法始于对患病的人类细胞中失调通路的理解，并揭示新的靶点和药物，以生成在临床上有更高成功率的首创方法。通过其行业领先的AI/ML赋能平台并利用单细胞转录组学，该公司正在揭示复杂疾病的新型可成药生物学，并推进丰富且高度差异化的的小分子项目管道。

The company's lead program, CLY-124, is a potential first-in-class small molecule developed for the treatment of sickle cell disease. CLY-124 induces fetal hemoglobin via a novel target identified using Cellarity's platform and is expected to enter clinical development in mid-2025. .

公司的主导项目CLY-124是一种潜在的首创新小分子，用于治疗镰状细胞病。 CLY-124通过使用Cellarity平台确定的新靶点诱导胎儿血红蛋白，预计将在2025年年中进入临床开发阶段。

About Cellarity

关于Cellarity

Founded by Flagship Pioneering in 2019, Cellarity is redefining how medicines are created by starting with an understanding of the cellular dysfunction that drives disease

Cellarity 由 Flagship Pioneering 于 2019 年创立，正在通过从理解驱动疾病的细胞功能障碍入手，重新定义药物的创造方式。

。

By shifting the drug discovery paradigm, Cellarity unravels biological complexity to develop therapies beyond the reach of traditional approaches. The company's platform combines proprietary AI/ML models with over 45 million single-cell transcriptomes, enabling the discovery of novel, actionable biology and the design of non-intuitive small molecule drug candidates across a broad range of diseases.

通过改变药物发现的范式，Cellarity揭示了生物复杂性，开发出传统方法无法企及的疗法。该公司的平台将专有的AI/ML模型与超过4500万个单细胞转录组相结合，能够发现新颖且可操作的生物学机制，并设计出针对广泛疾病的非直观小分子候选药物。

Cellarity's lead program is a small molecule for sickle cell disease, with additional programs in hematology and immunology, and an active collaboration with Novo Nordisk targeting metabolic dysfunction-associated steatohepatitis (MASH). For more information, visit .

Cellarity的主要项目是一种针对镰状细胞病的小分子药物，同时还有其他血液学和免疫学项目，并且与诺和诺德合作开展针对代谢功能障碍相关脂肪性肝炎（MASH）的项目。欲了解更多信息，请访问。

www.cellarity.com

。

About Flagship Pioneering

关于旗舰先锋

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than

旗舰先锋（Flagship Pioneering）发明并构建生物平台公司，每家公司都有潜力开发多种产品，从而改变人类健康或可持续发展。自2000年成立以来，Flagship已经发起并培育了100多个科学创业项目，产生了超过

$60 billion

600亿美元

in aggregate value. Flagship is operating with

总价值。旗舰正在运营

$14 billion

140亿美元

of assets under management as of its latest capital raise,

截至其最新一轮融资时的资产管理规模，

announced

宣布

在